T3D Therapeutics Inc receives approval to begin Alzheimer’s study
RESEARCH TRIANGLE PARK: T3D Therapeutics, Inc., a Research Triangle Park, NC-based developer of Alzheimer’s disease therapies, announced today that the Division of Neurology Products of the U.S. Food and Drug Administration has approved the company’s Investigational New Drug (IND) application to begin a Phase 2a clinical study of T3D-959, the company’s lead product candidate, in patients with mild-to-moderate Alzheimer’s disease.
